Portola Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care Conference
24 Février 2014 - 2:00PM
Portola Pharmaceuticals (Nasdaq:PTLA) today announced that William
Lis, chief executive officer, will present at the Cowen and Company
34th Annual Health Care Conference on Monday, March 3, 2014, at
2:10 p.m. Eastern Time in Boston.
The presentation will be webcast live and available for replay
from Portola's website at www.portola.com in the Investor Relations
section.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company focused
on the development and commercialization of novel therapeutics in
the areas of thrombosis and hematology.
Betrixaban
Portola's wholly-owned lead compound, betrixaban, is a novel,
oral, once-daily Factor Xa inhibitor in Phase 3 development for
extended-duration prophylaxis of venous thromboembolism (VTE) in
acute medically ill patients. Betrixaban's properties may be
uniquely suited to potentially demonstrate efficacy without
significantly increasing bleeding in this patient population.
Currently, there is no anticoagulant approved for extended-duration
VTE prophylaxis in acute medically ill patients.
Andexanet Alfa*
Portola's second lead development candidate, andexanet alfa
(PRT4445), has the potential to be a first-in-class reversal agent
to directly reverse the effects of Factor Xa inhibitors in patients
who suffer a major bleeding episode or who require emergency
surgery. Portola has entered into clinical collaboration agreements
with all of the manufacturers of direct Factor Xa inhibitors,
including Bristol-Myers Squibb and Pfizer (Eliquis® [apixaban]),
Bayer HealthCare and Janssen Pharmaceuticals (XARELTO®
[rivaroxaban]), and Daiichi Sankyo (Savaysa™ [edoxaban]), while
retaining all commercial rights to the program. Andexanet alfa has
been designated as a breakthrough therapy by the U.S. Food and Drug
Administration.
Cerdulatinib* (PRT2070) and PRT2607
Portola's third wholly-owned product candidate, cerdulatinib
(PRT2070), is an orally available kinase inhibitor that uniquely
inhibits two validated tumor proliferation pathways -- spleen
tyrosine kinase (Syk) and janus kinase (JAK). It is currently being
studied in patients with leukemias or lymphomas with a focus on
genetically-defined subtypes, as well as in patients who have
failed therapy due to relapse or acquired mutations. Portola's
fourth program is partnered with Biogen Idec and is focused on the
development of PRT2607, a selective Syk inhibitor.
For more information, visit www.portola.com and follow the
company on Twitter @Portola_Pharma.
*Andexanet alfa and cerdulatinib are proposed International
Nonproprietary Names (pINN).
CONTACT: Investor Contact:
Alexandra Santos
Portola Pharmaceuticals
ir@portola.com
650.246.7239
Media Contact:
Joey Fleury
BrewLife
jfleury@brewlife.com
415.946.1090
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024